BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers

  Latest News

Singapore’s Nanyang Biologics Plans to Go Public on Nasdaq in US $1.5 Billion SPAC Deal

by Andrii Buvailo, PhD  (contributor )   •   Oct. 2, 2025

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Biotech Ventures   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Singapore’s Nanyang Biologics (NYB), a company working at the intersection of biodiversity and artificial intelligence, is preparing to list on Nasdaq through a US$ 1.5 billion business combination with RF Acquisition Corp II, a U.S. special purpose acquisition company. The deal, expected to close in the first half of 2026, would give NYB public market access while keeping its original backer, Hong Kong–listed The9 Limited, as a major shareholder.

#advertisement
AI in Drug Discovery Report 2025

Unlike many drug discovery firms that rely on synthetic chemical libraries, NYB is building one of the world’s largest collections of molecules from natural sources—plants, fungi, and microbes. These compounds are then screened using its proprietary AI platform, DTIGN (Drug-Target Interaction Graph Neural Network), which applies graph neural networks and protein language models to predict how molecules interact with disease targets. Early results suggest the system identifies promising candidates more efficiently than conventional docking methods (with an average improvement of 27.03%).

To ensure predictions hold up, NYB runs a full cycle of laboratory validation—ranging from mechanism-of-action studies to pharmacokinetics and toxicity testing—before advancing compounds toward the clinic. Its lead drug candidate, NB-A002, targets ILF2, a protein long viewed as undruggable, and is aimed at cancers caused by DNA damage repair deficiencies and resistance to existing therapies.

The company has also secured collaborations with Nvidia, Hewlett Packard Enterprise, and Equinix to provide the computing power and secure infrastructure needed to scale AI-driven discovery.

With a growing natural compound library and an AI platform tailored to uncover hidden interactions, NYB is positioning itself at the frontier of synthetic lethality and precision oncology—fields where both the scientific and clinical stakes are high.

Topic: Biotech Ventures

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.